Mitragynine

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcKratom Use: An Emerging Perioperative Nursing Concern
3. 2026-09-07srcClinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom
4. 2026-09-07srcPrediction of physicochemical and pharmacokinetic properties of botanical constituents by computational models
5. 2026-09-07srcClinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)
6. 2026-09-07srcThe abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research
7. 2026-09-07srcAssessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats
8. 2026-09-07srcRespiratory effects of oral mitragynine and oxycodone in a rodent model
9. 2026-09-07srcAn exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans
10. 2026-09-07srcQuantification of 11 kratom alkaloids including mitragynine and its main metabolites in human plasma using LC-MS/MS
11. 2026-09-07srcKratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal
12. 2026-09-07srcFatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction
13. 2026-09-07srcIntrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa)
14. 2026-09-07srcKratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review
15. 2026-09-07srcAn insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine
16. 2026-09-07srcPatterns of Kratom use and health impact in the US-Results from an online survey
17. 2026-09-07srcThe Mitragyna speciosa (kratom) alkaloid mitragynine: Analysis of adrenergic alpha2 receptor activity in vitro and in vivo
18. 2026-09-07srcAn accidental poisoning with mitragynine
19. 2026-09-07srcMini review: Potential therapeutic values of mitragynine as an opioid substitution therapy
20. 2026-09-07srcThe medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse
21. 2026-09-07srcMitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit beta-Arrestin-2
22. 2026-09-07src7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects
23. 2026-09-07srcInvestigating Opioid Receptor Activity through Biocatalytic Halogenation and Oxidation of Mitragynine
24. 2026-09-07srcIn Vitro Pharmacology of Mitragynine at alpha-Adrenoceptors
25. 2026-09-07srcPhysiologically Based Pharmacokinetic Model for Clinical Translation and Prediction of Drug Interaction of the Major Kratom Alkaloid, Mitragynine
26. 2026-09-07srcNon-equilibrium snapshots of ligand efficacy at the mu-opioid receptor
27. 2026-09-07srcInsights into distinct signaling profiles of the muOR activated by diverse agonists
28. 2026-09-07srcChemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions
29. 2026-09-07srcMapping partial agonism of mitragynine at the mu-opioid receptor through molecular dynamics and Markov state modelling analysis
30. 2026-09-07srcSeverity of Pain and Sleep Problems during Kratom (Mitragyna speciosa Korth.) Cessation among Regular Kratom Users
31. 2026-09-07srcSeverity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal Symptoms
32. 2026-09-07srcMitragynine 'Kratom' related fatality: a case report with postmortem concentrations
33. 2026-09-07srcSelf-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey
34. 2026-09-07srcUse of Kratom, an Opioid-like Traditional Herb, in Pregnancy
35. 2026-09-07srcA drug fatality involving Kratom
36. 2026-09-07srcFatality of 33-Year-Old Man Involving Kratom Toxicity
37. 2026-09-07srcSelf-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)
38. 2026-09-07srcTranslating Kratom-Drug Interactions: From Bedside to Bench and Back
39. 2026-09-07srcFollowing the Roots of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries
40. 2026-09-07srcCharacteristics of deaths associated with kratom use
41. 2026-09-07srcUnusual Presentation of Kratom Overdose With Rhabdomyolysis, Transient Hearing Loss, and Heart Failure
42. 2026-09-07srcChemistry and Pharmacology of Analgesic Indole Alkaloids from the Rubiaceous Plant, Mitragyna speciosa
43. 2026-09-07srcNeonatal Abstinence Syndrome Due to Maternal Kratom Use
44. 2026-09-07srcPharmacokinetics of mitragynine in man
45. 2026-09-07srcKratom Dependence and Treatment Options: A Comprehensive Review of the Literature
46. 2026-09-07srcNatural drugs, not so natural effects: Neonatal abstinence syndrome secondary to kratom
47. 2026-09-07srcThe Chemical and Pharmacological Properties of Mitragynine and Its Diastereomers: An Insight Review
48. 2026-09-07srcHepatotoxicity Induced by the 3Ks: Kava, Kratom and Khat
49. 2026-09-07srcHuman Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder
50. 2026-09-07srcClinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants
51. 2026-09-07srcNovel case of maternal and neonatal kratom dependence and withdrawal
52. 2026-09-07srcKratom Legal Status - US DEA 2016 Scheduling Withdrawal; UK PSA 2016; Australia Schedule 9; WHO ECDD 2021 pre-review
53. 2026-09-07srcMitragynine: first isolated 1921 by Ellen Field; structure established by Beckett et al. 1965; absolute configuration confirmed by Zacharias et al. 1965
54. 2026-09-04issueIssued emergency
55. 2026-09-04issueIssued info_card
56. 2026-09-04issueIssued notice
57. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
58. 2026-06-04publicationPublication — backfill
59. 2026-05-08revisionRevision 1
60. 2026-05-08absenceSearched Multiple sources for "mitragynine Ki MOR KOR DOR binding affinity values" — no results
61. 2026-05-08genGeneration — pipeline-v5 · with 2 morepipeline-v5
62. 2026-05-08rungeneration run

The same entries, as forms: six forms.